

## News Release

# Lonza's Fully Automated Plate-Based Robotic Solution Enables Simple, Fast and Reliable Endotoxin Detection

**Walkersville, MD (USA) / Basel (CH), 25 April 2019** – Lonza today announced the global availability of the world's first fully automated and integrated plate-based PyroTec™ PRO Robotic Solution for endotoxin testing. Combining the speed and reproducibility of a robotic liquid handling platform with the power of version 6.0 of Lonza's market-leading WinKQCL™ Software, the system simplifies and accelerates endotoxin testing of parenteral pharmaceuticals regardless of sample complexity.

"At Lonza we are committed to developing new technologies to enable a safer and healthier living," said Allen Burgenson, Global Subject Matter Expert for Testing Services at Lonza. "In line with this vision, our new PyroTec™ PRO Robotic Platform offers quick time-to-result to expedite the delivery of safe medicines to improve patient healthcare. Scientists at QC testing laboratories can feel confident that the generated results will result in a reduction in human error, which will ultimately benefit patient safety."

Conventional endotoxin detection methods for parenteral pharmaceuticals are labor-intensive and error-prone, as they involve manual data entry and template set-up steps. As a consequence, the reliability of results can be compromised and the retest rate increased. At the same time, no metadata is associated with the manual steps, which limit traceability and the laboratory's audit capability.

"Less work for quicker and better results – that is Lonza's simple yet profound goal for our endotoxin testing customers," said Robert Porzio, Product Manager for Endotoxin Detection at Lonza. "Our PyroTec™ PRO Automated Robotic Solution reduces manual intervention considerably, minimizing the human error potential and the need for repeat test runs – all of which help enhance laboratory efficiencies. As a fully automated system, the PyroTec™ PRO Solution captures preparation metadata, adding traceability into tracking, trending and audit controls."

The PyroTec™ PRO Solution is being tested for ease-of-use in a trial carried out at Lonza's Chemical and Microbial Manufacturing site in Visp (CH).

Dr. Jan Erik Rau, Head of the QC Microbiology Department at the site, explained: "The user will be able to operate the system without any programming or scripting knowledge. The robot automatically executes all processing required to complete an analytical run, while the intuitive WinKQCL™ Software v6.0 receives and saves the results and then transfers them into and out of laboratory information management systems or Lonza's MODA™ Solution."

Additionally, the platform has been designed intrinsically to follow the U.S. Food and Drug Administration's (FDA's) Process Analytical Technology and Data Integrity Initiatives and to comply with the U.S. Pharmacopeia Bacterial Endotoxin Test guidance.

More information is available on [www.lonza.com/endotoxin-automation](http://www.lonza.com/endotoxin-automation).

### About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and

offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at [www.lonza.com](http://www.lonza.com).

#### **Lonza Contact Information**

##### **Petra Haberkamm**

Manager Marketing Communications  
Lonza Cologne GmbH  
Tel +49 221 991990  
[petra.haberkamm@lonza.com](mailto:petra.haberkamm@lonza.com)

##### **Constance Ward**

Head External Communications  
Lonza Group Ltd  
Tel +41 61 316 8840  
[constance.ward@lonza.com](mailto:constance.ward@lonza.com)

#### **Additional Information and Disclaimer**

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.